1. Volume 135, Issue 1, Pages 100-110 (July 2008)
Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial 
Vlad Ratziu, Philippe Giral, Sophie Jacqueminet, Fréderic Charlotte, Agnès Hartemann–Heurtier, Lawrence Serfaty, Philippe Podevin, Jean–Marc Lacorte, Carole Bernhardt, Eric Bruckert, André Grimaldi, Thierry Poynard 
Gastroenterology 
Volume 135, Issue 1, Pages (July 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Difference in the histologic score for steatosis between EOT and baseline liver biopsy specimens in both rosiglitazone (black circles) and placebo (white circles). Steatosis is expressed as the percentage of hepatocytes containing fat droplets. Responders for steatosis (ie, patients having lost >30% during treatment) are those on or below the dashed line.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
ALT course during therapy. Results are expressed as means (±SD) of fold elevation over baseline values at each time point during treatment and at EOT (month 12) and end of follow-up (month 16). (A) Rosiglitazone (black circles) and placebo (white circles); mean ALT values were significantly lower in the rosiglitazone group at months 4, 8, and 12. (B) Responders for steatosis (black circles) and nonresponders (white circles); mean ALT values were significantly lower in responders at months 8 and 12.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

4. Figure 3
Changes in serum adiponectin levels during treatment. (A) Serum adiponectin level at baseline (month 0 [M0]) and at EOT in patients treated with rosiglitazone (n = 12) and those receiving placebo (n = 10); P = .04; error bars represent SD. (B) Correlation between changes in serum adiponectin level (ratio EOT/M0) and changes in histologic score of steatosis during treatment (difference between steatosis on the EOT biopsy and baseline biopsy, EOT-M0); r = −0.54, P < .01, Spearman ranked test).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions